Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis
- PMID: 23355589
- PMCID: PMC3604510
- DOI: 10.1136/bcr-2012-008207
Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis
Abstract
Little evidence is available on the pharmacokinetics of antituberculous medication in premature infants. We report rifampicin (RMP) pharmacokinetics in an extremely premature, low-birthweight female infant born to a mother with known miliary tuberculosis. Intravenous RMP, isoniazid (INH), ciprofloxacin and amikacin were used, as the enteral route was not possible. Area under the curve calculations revealed low average RMP concentrations at doses of 5-10 mg/kg. We review the literature with regard to the dosing regimen and therapeutic drug levels of RMP and INH in premature infants and discuss issues of management. Evidence from this case suggests 10 mg/kg/day is the minimum dose required.
References
-
- Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK, 2010, London, UK Health Protection Agency Centre for Infections, 2010
-
- Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK, 2012 London, Health Protection Association, 2012
-
- Kothari A, Mahadevan N, Girling J. Tuberculosis and pregnancy-results of a study in a high prevalence area in London. Eur J Obstet Gynecol Reprod Biol 2006;126:48–55 - PubMed
-
- Graham SM. Treatment of paediatric TB: revised WHO guidelines. Paediatr Respir Rev 2011;12:22–6 - PubMed
-
- Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169–83 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources